Agency classClass IIOur severity:High FDA (Drugs)·D-0584-2026·Announced 2026-06-10

Lannett niacin extended-release tablets failed dissolution specifications during stability

Lannett Niacin Extended-release Tablets, 1,000 mg, are being recalled after a stability test returned an out-of-specification low result for Stage 3 dissolution at 24 hours.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 3/5 (High).

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall for a failed dissolution specification, which can alter the rate of drug release and creates a risk of harm with no injuries reported.

Plain-English summary

Niacin Extended-release Tablets, USP, 1,000 mg, in 90-count bottles, distributed by Lannett Company, Inc. of Philadelphia, NDC 62175-322-46, are being recalled. The action covers 3,984 bottles.

The stated reason is failed dissolution specifications: during 12-month long-term stability testing the product was out of specification, low, for Stage 3 dissolution at the 24-hour timepoint. Dissolution testing measures how a tablet releases its active ingredient over time, which matters particularly for an extended-release formulation. The FDA classified the action as Class II.

The affected lot is 25282724A, expiry 2027/01. Distribution was nationwide within the United States.

This is a prescription medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding the affected lot should contact their pharmacy or prescriber about a replacement supply.

The recalled product

Product: NIACIN (NIACIN)
Brand: NIACIN
Manufacturer: Lannett Company Inc.
Category: Drug — Extended-release tablet
Hazard: failed-dissolution
extended-release
stability-testing
class-ii
prescription-drug
Affected units: 3,984

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

Lot #: 25282724A
Exp. Date 2027/01

UPCs (1)

0362175320469

Distribution

Distributed nationwide across the United States.

Same brand · NIACIN

Moderate
Niacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
Moderate
Niacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-11-26
Moderate
Niacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-29
Moderate
Prescription Niacin Tablets Recalled for Microbial Contamination
FDA (Drugs) · 2024-01-31
High
Niacin Extended-Release Tablets Recalled for Manufacturing Microbial Contamination
FDA (Drugs) · 2024-01-31

Same manufacturer · Lannett Company Inc.

See all →

High
Amphetamine extended-release capsules contain immediate-release pellets after label mix-up
FDA (Drugs) · 2026-07-08
Low
Primidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
High
Amphetamine salt tablets recalled after bottles contained a lower strength tablet
FDA (Drugs) · 2025-09-17
High
Lisdexamfetamine 40 mg bottles recalled after being filled with 30 mg capsules
FDA (Drugs) · 2025-09-03
High
Prescription Drug Lisdexamfetamine Dimesylate Recalled for Failed Content Uniformity
FDA (Drugs) · 2024-12-11

Same hazard · failed dissolution